CFO
MRVI icon

Callan Family Office’s Maravai LifeSciences MRVI Stock Holding History

Callan Family Office’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,485
Closed -$47.1K – 1163
2025
Q4 		$47.1K Buy
14,485
+4,230
+41% +$14.2K ﹤0.01% 1093
2025
Q3 		$29.4K Hold
10,255
– – ﹤0.01% 840
2025
Q2 		$24.7K Buy
+10,255
New +$21.6K ﹤0.01% 907

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Callan Family Office's MRVI Position: Q1 2026 in Review

Callan Family Office sold out of Maravai LifeSciences (MRVI) in Q1 2026, closing a stake of 14,485 shares — an estimated $47.1K sold.

Callan Family Office first reported a position in MRVI in Q2 2025 and held it in 3 quarters. The position peaked at $47.1K in Q4 2025. 158 funds tracked by Wall St. Rank hold MRVI as of Q1 2026.

  • Callan Family Office reported no remaining Maravai LifeSciences position as of Q1 2026 after selling out during the quarter.
  • Callan Family Office sold 14,485 Maravai LifeSciences shares in Q1 2026, an estimated $47.1K.
  • Callan Family Office first reported a position in Maravai LifeSciences in Q2 2025 and held it in 3 quarters.
  • Callan Family Office's Maravai LifeSciences position peaked at $47.1K in Q4 2025.
  • 158 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2026.

Based on Callan Family Office's 13F filing for Q1 2026, filed 13 May 2026.